NCT02244021View on ClinicalTrials.gov

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

October 31, 2017

Conditions
Relapsed/Refractory Hodgkin's Lymphoma
Interventions
DRUG

BRENTUXIMAB VEDOTIN

"Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT."

Trial Locations (7)

Unknown

"Istituto di Ematologia L. & A. Seragnoli , Policlinico S. Orsola Malpighi", Bologna

Ematologia, IRCCS AOU San Martino-IST, Genova

Ematologia Ospedale Vito Fazzi, Lecce

Ematologia e Unità BMT IRCCS Istituto Nazionale dei Tumori, Milan

Università degli Studi di Modena e Reggio Emilia, D.A.I di Medicina diagnostica clinica e sanità pubblica, AOU Policlinico, Modena

Dipartimento di Oncologia Medica ed Ematologia, Istituto Humanitas, Rozzano

SC Ematologia - Azienda Ospedaliera AO Città della Salute e della Scienza, Torino

All Listed Sponsors
lead

Fondazione Italiana Linfomi - ETS

OTHER

NCT02244021 - BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV | Biotech Hunter | Biotech Hunter